Hutchison China Meditech Limited Chi-Med to Announce 2016 HY Financial Results (1164D)
05 July 2016 - 4:00PM
UK Regulatory
TIDMHCM
RNS Number : 1164D
Hutchison China Meditech Limited
05 July 2016
Chi-Med to Announce 2016 Half-Year Financial Results
London: Tuesday, July 5, 2016: Hutchison China MediTech Limited
("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its interim
results for the six months ended June 30, 2016 on Tuesday, August
2, 2016 at 7:00 am British Summer Time (BST).
An analyst presentation will be held at 9:00 am BST (4:00 pm
Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London
Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the
company website at www.chi-med.com/investors/event-information/.
The presentation will be available to download before the analyst
presentation begins.
For North America based analysts and investors, Chi-Med will
also host a conference call with Q&A at 9:00 am Eastern
Daylight Time (2:00 pm BST).
Details of the analyst presentation and conference call dial-in
will be provided in the financial results announcement. A replay
will also be available on the website shortly after each event.
NOTES TO EDITORS
About Chi-Med
Chi-Med is a China-based, globally-focused healthcare group
which researches, develops, manufactures and sells pharmaceuticals
and health-related consumer products. Its Innovation Platform,
Hutchison MediPharma Limited, is focused on discovering, developing
and commercializing innovative therapeutics in oncology and
autoimmune diseases. Its pipeline of eight novel oral compounds for
cancer and inflammation is in development in North America, Europe,
Australia and Greater China.
Chi-Med's Commercial Platform manufactures, markets and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Jillian Connell, The Trout Group +1 (646) 378 2956 jconnell@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORVZLBBQDFBBBZ
(END) Dow Jones Newswires
July 05, 2016 02:00 ET (06:00 GMT)